fusion pharmaceuticals (www.fusionpharma.com) is a new pharmaceutical company located in hamilton, ontario, canada, that is focused on becoming the leader in the targeted alpha therapy field. fusion will exploit its unique expertise in linking medical isotopes to targeting molecules to create highly effective therapeutics. in addition to its lead program, fpx-01, fusion is building a pipeline of products through a protein discovery platform, that allows for the rapid screening of new targeting molecules to promote biomarker localization of alpha emitting medical isotopes. fusion’s technology development team also has proprietary methods for introducing alpha emitters into targeting molecules.
Company profile
Ticker
FUSN
Exchange
Website
CEO
John Valliant
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
Corporate docs
Subsidiaries
Fusion Pharmaceuticals US Inc. ...
FUSN stock data
Latest filings (excl ownership)
DEFA14A
Additional proxy soliciting materials
23 Apr 24
8-K
Other Events
23 Apr 24
8-K/A
Other Events
12 Apr 24
10-K/A
2023 FY
Annual report (amended)
12 Apr 24
PREM14A
Preliminary proxy related to merger
10 Apr 24
8-K
Other Events
9 Apr 24
S-8
Registration of securities for employees
20 Mar 24
10-K
2023 FY
Annual report
20 Mar 24
8-K
Fusion Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Announces Clinical Program Updates
20 Mar 24
DFAN14A
Additional proxy materials by non-management
19 Mar 24
Latest ownership filings
SC 13G/A
FEDERATED HERMES, INC.
8 Apr 24
SC 13D
FEDERATED HERMES, INC.
25 Mar 24
SC 13D/A
HealthCap VII, L.P.
20 Mar 24
SC 13D/A
HealthCap VII, L.P.
7 Mar 24
SC 13G/A
CANADA PENSION PLAN INVESTMENT BOARD
14 Feb 24
SC 13G/A
Avidity Partners Management LP
13 Feb 24
SC 13G/A
FMR LLC
9 Feb 24
SC 13G
PERCEPTIVE ADVISORS LLC
19 Jan 24
SC 13G/A
FEDERATED HERMES, INC.
18 Jan 24
4
Christopher P Leamon
5 Jan 24
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | |
---|---|---|---|---|
Revenue | ||||
Cost of revenue | ||||
Operating income | ||||
Operating margin | ||||
Net income | ||||
Net profit margin | ||||
Cash on hand | ||||
Change in cash | ||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 28.11 mm | 28.11 mm | 28.11 mm | 28.11 mm | 28.11 mm | 28.11 mm |
Cash burn (monthly) | 1.73 mm | 6.62 mm | 6.46 mm | 7.99 mm | 6.28 mm | 6.94 mm |
Cash used (since last report) | 11.74 mm | 44.94 mm | 43.90 mm | 54.29 mm | 42.65 mm | 47.10 mm |
Cash remaining | 16.37 mm | -16.83 mm | -15.79 mm | -26.18 mm | -14.55 mm | -19.00 mm |
Runway (months of cash) | 9.5 | -2.5 | -2.4 | -3.3 | -2.3 | -2.7 |
Institutional ownership, Q2 2023
69.9% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 42 |
Opened positions | 6 |
Closed positions | 2 |
Increased positions | 10 |
Reduced positions | 4 |
13F shares | Current |
---|---|
Total value | 226.93 bn |
Total shares | 59.34 mm |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
FHI Federated Hermes Inc - Ordinary Shares | 10.63 mm | $49.77 bn |
Avidity Partners Management | 5.70 mm | $26.62 bn |
FMR | 4.68 mm | $21.91 bn |
HealthCap VII | 3.81 mm | $19.53 mm |
JNJ Johnson & Johnson | 3.67 mm | $17.14 bn |
VAR Varian Medical Systems | 3.26 mm | $38.27 mm |
Orbimed Advisors | 3.12 mm | $14.58 bn |
Canada Pension Plan Investment Board | 3.12 mm | $14.59 bn |
Adams Street Partners | 2.95 mm | $13.77 bn |
Deerfield Management | 2.82 mm | $13.18 bn |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
4 Jan 24 | John Valliant | RSU Common Stock | Grant | Acquire A | No | No | 0 | 192,200 | 0.00 | 192,200 |
4 Jan 24 | John Valliant | Stock Option Common Stock | Grant | Acquire A | No | No | 8.44 | 320,400 | 2.70 mm | 320,400 |
4 Jan 24 | Dmitri Bobilev | RSU Common Stock | Grant | Acquire A | No | No | 0 | 91,000 | 0.00 | 91,000 |
4 Jan 24 | Dmitri Bobilev | Stock Option Common Stock | Grant | Acquire A | No | No | 8.44 | 151,700 | 1.28 mm | 151,700 |
4 Jan 24 | Eric Burak | RSU Common Stock | Grant | Acquire A | No | No | 0 | 63,700 | 0.00 | 63,700 |
4 Jan 24 | Eric Burak | Stock Option Common Stock | Grant | Acquire A | No | No | 8.44 | 106,100 | 895.48 k | 106,100 |
4 Jan 24 | Crowley John J | RSU Common Stock | Grant | Acquire A | No | No | 0 | 63,700 | 0.00 | 63,700 |
4 Jan 24 | Crowley John J | Stock Option Common Stock | Grant | Acquire A | No | No | 8.44 | 106,100 | 895.48 k | 106,100 |
News
TD Cowen Downgrades Fusion Pharmaceuticals to Hold
16 Apr 24
AstraZeneca Hikes Annual Dividend By 7% Just Before Vote On Its CEO's Pay Package Boost
11 Apr 24
AstraZeneca CEO Highlights Decade-Long Sales Goal Of $45B Along With Investor Doubts As It Lags In Weight Loss Race
2 Apr 24
RBC Capital Reiterates Sector Perform on Fusion Pharmaceuticals, Maintains $21 Price Target
21 Mar 24
Wedbush Reiterates Neutral on Fusion Pharmaceuticals, Maintains $24 Price Target
21 Mar 24
Press releases
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates HMST, CHX, FUSN, DRQ
12 Apr 24
Kuehn Law Encourages HMST, CHX, FUSN, and DRQ Investors to Contact Law Firm
12 Apr 24
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates FUSN, LABP, JBT
9 Apr 24
Fusion Pharmaceuticals Announces Presentation of Interim Data from the Phase 2 TATCIST Clinical Trial Evaluating FPI-2265 at the AACR Annual Meeting 2024
9 Apr 24
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates FUSN, LABP, DOMA
5 Apr 24